STAT Plus is STAT’s premium subscription service, offering access to exclusive, in-depth coverage. We write about pharma and biotech news on Wall Street, policy developments in Washington, early science and clinical trials, and disruption in health care in Silicon Valley and beyond.
STAT Plus is an indispensable resource for biotech, pharma, and health care policy professionals. Here’s what we deliver:
Market-moving biotech insight — from startup funding and partnering, to clinical trial readouts and company analysis.
Profiles of the power players and personalities shaping the industry.
Analysis of the technological breakthroughs and innovations disrupting the industry.
Extensive coverage of Congress, the FDA, the NIH, drug pricing, patent issues, and biopharma lobbying.
What else is included?
Get access to an exclusive set of benefits with STAT Plus, including: